About 36,180 results

ALLMedicine™ Leukemia Center

Research & Reviews  13,619 results

The prognostic role of NKG2A expression for patients with chronic myeloid leukemia afte...
Leukemia & Lymphoma; Xu Z, Yin J et. al.

Jun 28th, 2022 - This study aims to evaluate the possibility of tyrosine kinase inhibitors (TKIs) discontinuation in chronic myeloid leukemia (CML) patients who obtained sustained deep molecular response (DMR) and to explore the prognostic role of NK cells in trea...

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic l...
https://doi.org/10.1038/s41375-022-01629-7 10.2217/fon-2017-0442 10.1182/asheducation-2013.1.138 10.1038/s41375-018-0313-8 10.1182/blood-2017-09-806398 10.1056/NEJMoa1509388 10.1182/blood-2014-10-606038 10.1056/NEJMoa1815281 10.1056/NEJMoa1713976 10.1016/S1470-2045(18)30788-5
Leukemia von Tresckow J, Cramer P et. al.

Jun 26th, 2022 - Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.|2022|von Tresckow J,Cramer P,Robrecht S,Langerbeins P,Fink AM,|

Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy and Monitoring.
American Journal of Hematology; Jabbour E, Kantarjian H

Jun 26th, 2022 - Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults DIAGNOSIS: CML is characterized by a balanced genet...

see more →

Guidelines  15 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... Deininger MW, Shah NP et. al.

Oct 7th, 2020 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phas...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical ...
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Feb 6th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

see more →

Drugs  201 results see all →

News  632 results

No Survival Gain From High-Dose Cytarabine Consolidation in AML

Jun 23rd, 2022 - The study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Regarding consolidation therapy for younger patients with acute myeloid leukemia (AML), there was no survival benefit from taking high-dos...

Venetoclax Combos Improve Progression-Free Survival in CLL

Jun 15th, 2022 - Use of the targeted therapy combination of venetoclax plus obinutuzumab for fit patients with chronic lymphocytic leukemia (CLL) significantly improved progression-free survival (PFS) at 3 years compared with standard chemoimmunotherapy, new phase...

Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML

Jun 13th, 2022 - The potent oral FLT3 inhibitor quizartinib more than doubled overall survival among patients newly diagnosed with FLT3-ITD-positive acute myeloid leukemia (AML) compared with standard chemotherapy, new phase 3 data show. Among adults who received ...

Similar Survival, Less Toxicity With Decitabine vs Chemo in AML

Jun 12th, 2022 - Older, fit patients with acute myeloid leukemia (AML) pretreated with a 10-day regimen of decitabine (Dacogen) prior to allogeneic hematopoietic stem cell transplantation had similar overall survival compared with those receiving conventional inte...

Intermediate-Risk Acute Myeloid Leukemia

May 19th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York Ci...

see more →

Patient Education  5 results see all →